Please provide your email address to receive an email when new articles are posted on . There were several important FDA approvals for GI conditions over the past year, including the first treatment ...

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 Carlsbad, CA, Sept. 06, 2023 ...

Ironwood Pharmaceuticals has established itself as a leader in the gastrointestinal healthcare space with its innovative products and pipeline development. The demand for LINZESS, a therapy for ...